About Prosonix
Prosonix is a company based in Oxford (United Kingdom) founded in 2006 was acquired by Circassia Pharmaceuticals in May 2015. Prosonix has raised $27.05 million across 2 funding rounds from investors including Circassia Pharmaceuticals, Gimv and Quest for Growth. The company has 32 employees as of December 31, 2021. Prosonix operates in a competitive market with competitors including aTyr Pharma, ReCode Therapeutics, GEn1E, Enterprise Therapeutics and Ikaria, among others.
- Headquarter Oxford, United Kingdom
- Employees 32 as on 31 Dec, 2021
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Circassia Limited
-
Annual Revenue
$17.94 M (USD)0as on Dec 31, 2020
-
Net Profit
-$11.66 M (USD)0as on Dec 31, 2020
-
EBITDA
Not available
-
Total Equity Funding
$27.05 M (USD)
in 2 rounds
-
Latest Funding Round
$27.05 M (USD), Series B
May 21, 2012
-
Investors
Circassia Pharmaceuticals
& 6 more
-
Employee Count
32
as on Dec 31, 2021
-
Acquired by
Circassia Pharmaceuticals
(May 18, 2015)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Prosonix
Prosonix has successfully raised a total of $27.05M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $27.05 million completed in May 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Prosonix
Prosonix has secured backing from 7 investors, including venture fund investors. Prominent investors backing the company include Circassia Pharmaceuticals, Gimv and Quest for Growth.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity firm
|
Locked | Locked | Locked | |
|
Tech & life science focused stage agnostic VC firm investing primarily in Western Europe
|
Locked | Locked | Locked | |
|
Growth-stage life sciences and tech companies in Europe are funded.
|
Locked | Locked | Locked |
Investor details for Prosonix
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Prosonix
Investment portfolio details for Prosonix
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Prosonix
Detailed financials for Prosonix
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Prosonix Comparisons
Peer comparison for Prosonix
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Prosonix
Prosonix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as aTyr Pharma, ReCode Therapeutics, GEn1E, Enterprise Therapeutics and Ikaria, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Protein biologics are developed for treating rare diseases.
|
|
| Locked | Locked | Locked |
Precision medicines for lung-related diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of therapeutics for the treatment of inflammatory and rare diseases
|
|
| Locked | Locked | Locked |
Developer of therapeutic solutions for the treatment of respiratory diseases such as cystic fibrosis
|
|
| Locked | Locked | Locked |
Therapies for respiratory-related cardiopulmonary disorders are developed.
|
|
| Locked | Locked | Locked |
Developer of therapeutics for the treatment of respiratory diseases
|
Detailed competitors of Prosonix
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Prosonix
Complete news archive for Prosonix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Prosonix
Prosonix was founded in 2006 and raised its 1st funding round 1 year after it was founded.
Prosonix is headquartered in Oxford, United Kingdom. It is registered at Oxford, Oxfordshire, United Kingdom.
Prosonix is a funded company, having raised a total of $27.05M across 2 funding rounds to date.
As of Dec 31, 2021, the latest employee count at Prosonix is 32.
Annual revenue of Prosonix is $17.94M as on Dec 31, 2020.
Prosonix is a speciality pharmaceutical company developing a portfolio of inhaled respiratory medicines by design. Pipeline include: PSX1001PSX1050, a potent inhaled corticosteroid monotherapy for asthma and chronic obstructive pulmonary disease (COPD) in pressurised metered dose inhaler (pMDI); PSX1002, a long-acting muscarinic antagonist for COPD in pMDI; PSX2005 for asthma, SX2000 Novel combination medicines designed specifically for respiratory diseases based on Multi-component Particles (MCPs).
Prosonix's top competitors include aTyr Pharma, ReCode Therapeutics and Pulmatrix.
Prosonix has 7 investors. Key investors include Circassia Pharmaceuticals, Gimv, Quest for Growth, Entrepreneurs Fund, and Solon Ventures.